Coronavirus treatment: Biocon’s psoriasis drug Itolizumab approved by DCGI; full course for Rs 32,000

Coronavirus: Biocon founder and chairperson Kiran Mazumdar Shaw says that in a matter of about 120 days the company has moved from applying for commencement of trials on coronavirus patients to getting the final approval for commercialisation